Prophylaxis of HBV reactivation by vaccination enforcing post-transplant HBV immunity
- Conditions
- HSCT recipient with resolved infection of HBV
- Registration Number
- JPRN-UMIN000034113
- Lead Sponsor
- ational Center for Global Health and Medicine Genome Medical Science Project
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 109
Not provided
(1) anti-HCV antibody negative (2) anti-HIV antibody negative (3) HBV DNA>=1.3 Log IU/mL (4) anti-HBc antibody negative (5) seroconversion of anti-HBc antibody negative to positive after infusion of blood product (6) previous HBV reactivation (7) previous history of treatment using nucleoside analogue, or plan to prescribe nucleoside analogue for prophylaxis (8) anaphylaxis for previous vaccine (9) conditioning regimen has been started for first HSCT (10) complication of severe infection (11) hemodialysis has been started or planed to be induced (12) uncontrollable diabetics, hypertension or heart failure (13) woman during pregnant or lactation (14) patient who plan to move or plan to be followed by other institute during 2-year after HSCT (15) patient who is not been considered to be eligible to the study by a doctor in charge by miscellaneous reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBV reactivation
- Secondary Outcome Measures
Name Time Method